Why Celldex Therapeutics Is Getting Crushed

Celldex Therapeutics shares were absolutely crushed on Monday morning after the firm announced results to its midstage breast cancer study......»»

Category: blogSource: 247wallstApr 16th, 2018

MGIC, Juniper Networks Slide into Wednesday’s 52-Week Low Club

MGIC Investment Group, Celldex Therapeutics, Juniper Networks, and Healthcare Services Group all posted new 52-week lows on Wednesday......»»

Category: blogSource: 247wallstApr 18th, 2018

Celldex"s Phase II Breast Cancer Study Fails, Shares Plunge

Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastat.....»»

Category: smallbizSource: nytApr 17th, 2018

Celldex, Acacia Plummet into Monday’s 52-Week Low Club

Celldex Therapeutics, Acacia Communications, Apricus Biosciences, and all posted new 52-week lows Monday......»»

Category: blogSource: 247wallstApr 16th, 2018

Celldex"s stock plummets toward record low after failed drug study

Shares of Celldex Therapeutics Inc. plummeted 40% in premarket trade Monday toward a record low, after the drug.....»»

Category: topSource: marketwatchApr 16th, 2018

In the money put buyer opens a notable new position in Celldex Therapeutics

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 9th, 2018

Celldex Therapeutics Finishes 2017 With Plenty of Cash and High Hopes

The clinical-stage biotech awaits big news on its lead candidate in the second quarter of 2018......»»

Category: topSource: foxnewsMar 8th, 2018

Celldex Therapeutics (CLDX) CEO Anthony Marucci on Q3 2017 Results - Earnings Call Transcript

Celldex Therapeutics (CLDX) CEO Anthony Marucci on Q3 2017 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaMar 7th, 2018

Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on immuno-onc.....»»

Category: dealsSource: nytMar 1st, 2018

Celldex Therapeutics: Back Up The Truck Or Back Away?

Celldex Therapeutics: Back Up The Truck Or Back Away?.....»»

Category: topSource: seekingalphaFeb 8th, 2018

What to Expect From Celldex Therapeutics, Inc. in 2018

After a decades-long journey, 2018 could be the year Celldex Therapeutics transitions from a clinical-stage biotech to one with a product to sell......»»

Category: topSource: foxnewsJan 27th, 2018

Why Celldex Therapeutics Stock Reversed Course in November

Investors cheered Celldex's decision to expand its clinical activities last month......»»

Category: topSource: foxnewsDec 10th, 2017

Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.

Find out which of these cancer drug developers is a better stock pick at the moment......»»

Category: topSource: foxnewsNov 30th, 2017

Here"s Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017

This year has been disappointing for the biotech -- but 2018 could be an entirely different story......»»

Category: topSource: foxnewsNov 29th, 2017

Acorda Therapeutics Gets Crushed After Halting Parkinson’s Trial

Acorda Therapeutics saw its shares drop sharply following an announcement that it had paused new enrollment in a long-term safety study. In a sense, Acorda has halted this trial......»»

Category: blogSource: 247wallstNov 15th, 2017

Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up

Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday. Celldex Therapeutics, Inc. CLDX incurred third-quarter 2017 loss (adjusted fo.....»»

Category: worldSource: nytNov 8th, 2017

Celldex Reports Third Quarter 2017 Results

HAMPTON, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financ.....»»

Category: earningsSource: benzingaNov 7th, 2017

What"s Behind Celldex Therapeutics, Inc."s 16% Rally in September?

It looks like impatient investors anticipating news from an ongoing pivotal trial drove up the stock last month......»»

Category: topSource: foxnewsOct 6th, 2017

Reasons Why Celldex Therapeutics Is A Buy (Part 1)

Reasons Why Celldex Therapeutics Is A Buy (Part 1).....»»

Category: topSource: seekingalphaSep 21st, 2017

Acorda Therapeutics Shares Crushed After Receipt of FDA Refusal Letter

Acorda Therapeutics saw its shares get crushed early on Tuesday after the firm received a Refusal to File letter from the FDA in regards to its New Drug Application for Inbrija......»»

Category: blogSource: 247wallstAug 29th, 2017

Celldex Ends Phase II Enrollment for Breast Cancer Candidate

Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment. Celldex Therapeutics, Inc. CLDX announced com.....»»

Category: smallbizSource: nytAug 24th, 2017